BMO Capital Downgrades Gilead Sciences (GILD) to Market Perform
More News related to GILD
- Gilead (GILD) Lower On Fears of Flat HIV Growth Cited in BofA Downgrade, Another Analyst Takes Opposing View
- Notable Analyst Rating Changes 9/2: AMLN, LOW, GOOG Upgraded; GILD, DF, NSC Downgraded
- David Moenning's Daily State of the Markets: 9/2
- Banc of America Downgrades Gilead Sciences (GILD) to Neutral
- BeaconEquity.com Issues Technical Trade Alerts on BioPharmaceutical Stocks: CEGE, AMLN, DNA, GENZ, AMGN, GILD
BMO Capital downgrades Gilead Sciences (Nasdaq: GILD) from Outperform to Market Perform. Price target $55.
Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops and commercializes therapeutics in areas of unmet medical need.
Related Categories
DowngradesStocks Mentioned
-1.60Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
